Interesting study being planned for POTS with Efgartigimod. A monoclonal antibody fragment that binds other antibodies. Think of it like a pharmaceutical immunoadsorption without the extracorporeal circuit.
More info on the drug here ⬇️
https://www.argenx.com/pipeline/efgartigimod
More info...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.